Bepak parent company Consort Medical has announced a multi-year agreement with AstraZeneca to supply Bespak’s MDI valves and actuators for use in AstraZeneca’s Bevespi Aerosphere inhaler. The components for the project, which will be called VAL100, will be manufactured at Bespak’s King’s Lynn, UK facility.
The Bevespi Aerosphere glycopyrrolate/formoterol fumarate MDI was approved for the treatment of COPD by the FDA in April 2016. AstraZeneca acquired the product, formerly known as PT003, when it acquired Pearl Therapeutics in 2013.
Consort Medical CEO Jon Glenn commented, “We are delighted to have successfully concluded this agreement with AstraZeneca. This further reinforces the ongoing strength of our respiratory device franchise in the pMDI segment.”
Read the Consort Medical press release.
